Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis

NCT01395004 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01395004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01395004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2013
Enrollment
17 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis